High-Risk Prostate Cancer: Is Surgery Still an Option?
Most prostate cancer content focuses on low and intermediate risk disease — the slow-growing cancers, the active surveillance conversations, the "you have time to decide" reassurances. That is reasonable, because most prostate cancers detected today fall into those categories.
But some don't. And the patients sitting across the desk with high-risk disease are often the ones who feel most unsupported by what they find online.
This article is for them.
What makes prostate cancer "high risk"?
High-risk prostate cancer is defined by one or more of the following features:
PSA above 20 ng/mL
Grade Group 4 or 5 (Gleason 8, 9, or 10)
Clinical stage T3 or above — meaning the cancer appears to extend beyond the prostate capsule on examination or imaging
The presence of any one of these features places the cancer in the high-risk category. Having more than one — a high PSA and a high grade group, for example — increases concern further.
What high-risk means practically is that the cancer has a greater likelihood of having spread beyond the prostate itself, whether to adjacent tissues, lymph nodes, or elsewhere. This doesn't mean it has spread — only that the probability is higher, and that treatment planning has to account for that possibility.
Does high-risk mean surgery is off the table?
No. This is one of the most common misconceptions patients arrive with.
Surgery was historically considered less appropriate for high-risk prostate cancer, partly because early surgical series had worse outcomes in this group, and partly because radiation combined with hormone therapy has a well-established evidence base here. Both remain true — and surgery has nonetheless become a recognised first-line option for the right patient.
Radical prostatectomy is now a recognised, guideline-supported treatment for high-risk disease. In many patients, it forms the first step in a treatment pathway that may include further therapy depending on the final pathology and PSA course. The distinction matters. Surgery in this setting is not a gamble on a single operation. It is a deliberate choice, made with clear decision points built in.
The question is not "is surgery possible?" It is "is surgery the right first step for this patient, this cancer, and what comes after?"
What changes about surgery in high-risk disease?
Several things.
The operation is often more extensive. High-risk disease warrants pelvic lymph node dissection — removal of the lymph nodes in the pelvis to assess for microscopic spread and, in some cases, to treat it. This adds complexity and time to the operation.
Nerve-sparing decisions are different. With high-risk disease, the cancer may be close to or involving the neurovascular bundles. Attempting nerve-sparing when it risks leaving cancer behind is the wrong trade-off. In many high-risk cases, nerve-sparing on at least one side is limited or not attempted. This has to be discussed honestly before surgery.
The likelihood of needing further treatment is higher. Even after a technically successful operation, some patients with high-risk disease will have features on the pathology report — positive surgical margins, lymph node involvement, extracapsular extension — that suggest additional treatment may be needed. Radiation and/or hormone therapy after surgery is not a sign of failure; it is part of a planned multimodal pathway for many high-risk patients.
Staging matters more. Before recommending surgery for high-risk disease, careful staging is essential. This typically includes PSMA PET imaging, which can identify spread to lymph nodes or distant sites that would change the treatment recommendation entirely. Operating on a patient with distant spread that wasn't identified pre-operatively is not good surgical care.
Surgery versus radiation for high-risk disease
Both are established curative-intent options. For many patients the decision is genuinely close, and the right answer often involves both — not as a failure of planning, but as deliberate sequencing.
Radiation-based treatment for high-risk disease is typically external beam radiation combined with hormone therapy (androgen deprivation therapy). This is one of the most evidence-rich treatments in prostate oncology, with long-term data from large randomised trials. It is not the "non-surgical fallback." It is a first-line option with a strong track record.
Surgery in high-risk disease means accepting that further treatment may follow. For patients whose pathology reveals positive margins, lymph node involvement, or extracapsular extension, adjuvant or salvage radiation is an established next step — not a rescue, but an anticipated part of care for some. This has to be understood going in.
Neither approach is clearly superior across the board. The choice depends on:
Staging findings — particularly whether spread is present or suspected
Anatomy and fitness for a major operation
What side effects matter most — urinary, sexual and bowel considerations differ between surgery and radiation in both pattern and timing, including continence, erectile function and bowel effects
Whether specific tumour or anatomical features make one approach more appropriate technically
Patient preference after honest, unhurried explanation of both
For high-risk disease, I routinely recommend patients meet with a radiation oncologist as well as with me before deciding. This is not indecision. It is the standard I hold myself to: a patient choosing surgery over radiation for high-risk disease should make that choice having genuinely heard both perspectives — not because surgery was the first consultation they had.
What does a good surgical outcome look like in high-risk disease?
The goal is clear surgical margins and complete removal of the prostate and relevant tissue, with accurate pathological staging.
A clear surgical margin means no cancer cells at the edge of the removed specimen. In high-risk disease, positive margins are more common than in low-risk disease — not because surgery is done less carefully, but because the cancer is more likely to be close to or beyond the capsule. Where margins are positive, salvage radiation is an established and effective next step.
Lymph node involvement, if found, provides important staging information and guides decisions about further treatment.
The measure of a good outcome is not "never needing another treatment." It is: was the cancer removed as completely as possible, was staging accurate, and does the patient now have a clear plan for follow-up and any further treatment if needed.
Who is a good candidate for surgery in high-risk disease?
There is no universal checklist, but the patients most likely to be well-served by surgery in high-risk disease tend to have:
Disease that appears technically resectable — confined to the pelvis, without evidence of distant spread on PSMA PET
Fitness for a major operation and general anaesthetic
An understanding that further treatment may follow
A preference for the surgical pathway and its particular trade-offs, after honest discussion of alternatives
Disease for which surgery would add useful local control and clear pathological information, rather than simply proceeding because an operation is technically possible
Patients with very locally advanced disease, significant comorbidities, or evidence of distant spread are generally better served by non-surgical systemic approaches.
The conversation that matters most
High-risk prostate cancer consultations are among the most consequential in urology. The stakes are higher. The pathways are more complex. The patient sitting across the desk is usually frightened — and often carrying a version of the disease they've constructed from what they've read online, which may or may not reflect their actual situation.
What I try to do in this setting is be specific. Not "you have high-risk disease, here are your options" — but: here is your MRI, here is what your biopsy tells us about grade and distribution, here is what the PSMA PET does or doesn't show, and here is how I would think about your case specifically.
Some patients arrive having already decided they want surgery. Some arrive convinced they want radiation. I don't push back on the instinct, but I do slow it down. Both deserve a clear explanation of what the evidence actually shows for their risk profile, what each pathway would realistically involve, and what the plan is if things don't go as expected.
I involve radiation oncology early in high-risk cases — not as a referral away, but as part of the assessment. A patient who chooses surgery having genuinely heard the radiation oncology perspective is making a better-informed decision than one who chose surgery because it was the first door they walked through.
High-risk disease is not a reason to move fast. It is a reason to be thorough.
For more on the prostate cancer pathway including diagnosis, staging and treatment options, see Prostate Cancer. For information on robotic prostatectomy, see Robotic Radical Prostatectomy.
If you have been diagnosed with high-risk prostate cancer and want to discuss whether surgery is appropriate in your case, contact the rooms to arrange a consultation.
Clinical note: This article provides general information and is not a substitute for individual medical advice. Management of high-risk prostate cancer should be based on multidisciplinary assessment, careful staging and personalised discussion of treatment options.
Last reviewed: April 2026
About the author: Dr Deanne Soares is a Melbourne-based urologist with a subspecialist focus in robotic prostate, kidney and bladder cancer surgery.
